http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2004529175-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D235-26 |
| filingDate | 2002-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2004-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2004529175-A |
| titleOfInvention | 2H-benzimidazol-2-one, 1,3-dihydro-1- (2- {4- [3- (trifluoromethyl) phenyl] -1-piperazinyl} ethyl)-and its physiologically acceptable acids New use of addition salt |
| abstract | The present invention relates to 2H-benzimidazol-2-one, 1,3-dihydro-1- (2- {4- [3- (trifluoromethyl) phenyl] -1-piperazinyl} ethyl)- The use of an acceptable acid addition salt for the manufacture of a medicament for the treatment of extrapyramidal movement disorders. The extrapyramidal dyskinesia is idiopathic Parkinson's disease, a side effect due to administration of an anti-Parkinson's disease drug in idiopathic Parkinson's disease, dyskinesia caused by idiopathic Parkinson's disease and / or by long-term administration of an anti-Parkinson's disease drug, or , Parkinson's disease-like symptoms or Parkinson's disease-related syndromes resulting from Parkinson's disease-like symptoms. Another aspect of the invention is (I) 2H-benzimidazol-2-one, 1,3-dihydro-1- (2- {4- [3- (trifluoromethyl) phenyl] -1-piperazinyl} ethyl)-or its physiology as active ingredients An acid addition salt which is acceptable, and (II) a pharmaceutical composition comprising at least one anti-parkinsonian drug together with one or more pharmaceutically acceptable excipients. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012512145-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2008531715-A |
| priorityDate | 2001-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 57.